DOCSLIB.ORG

Alpha^ and Beta^Blocking Agents: Pharmacology and Properties

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

CURRENT DRUG THERAPY DONALD G. VIDT, MD AND ALAN BAKST, PharmD, EDITORS Alpha^ and beta^blocking agents: pharmacology and properties PROFESSOR B.N.C. PRICHARD • Adrenergic receptors have been separated into alpha and beta groups, which have then been further subdivided. Agents have been developed that block each type of receptor with varying degrees of specificity between the sub-types, leading to differences in pharmacodynamic profile. A more recent innovation has been the development of multiple action beta-blocking drugs, ie, those not only blocking the beta receptors but also posessing a peripheral vasodilator effect that may be due to alpha blockade, beta-2 stimulation, or a vasodilator action independent of either alpha or beta receptors. • INDEX TERMS: ALPHA BLOCKERS; BETA BLOCKERS; HYPERTENSION • CLEVE CLIN ] MED 1991; 58:33 7-350 HE CONCEPT that binding of Rosenblueth suggested that a transmitter released at catecholamines to receptors leads to differ- sympathetic nerve endings produced either inhibitory ing responses was first described by Langley, or excitatory responses as a result of combination with who in 1905 noted that a cell may make sympathin I or sympathin E at the receptor.3 Tmotor or inhibitory substances or both, and that "the The current classification of alpha and beta respon- effect of a nerve impulse depends upon the proportion ses is based on the classic work of Ahlquist,4 who of the two kinds of receptive substance which is af- studied six sympathomimetic amines and found two fected by the impulse."1 In 1906, Dale reported that patterns of reactivity. One group of actions, mediated ergot blocked the excitatory but not the inhibitory ac- by what were termed "alpha receptors," were principally tions of adrenaline.2 In 1933, Cannon and excitatory. The excitatory actions included vaso- constriction, as well as contraction of the uterus, ureter, and nictitating membrane. But alpha actions also in- cluded inhibitory actions, such as dilator pupillae and From the Department of Clinical Pharmacology, University Col- lege and Middlesex School of Medicine, University College Lon- intestinal relaxation. The most potent agent at these don, England. receptors was adrenaline, followed by noradrenaline. Address reprint requests to B.N.C.P., Head, Department of Clini- In the second group, mediated by what were termed cal Pharmacology, University College London, 5 University Street "beta receptors," inhibitory actions predominated. (The Rayne Institute), London WCIE 6JJ, England. This article was produced by Consultants in Medical Education, These inhibitory actions included vasodilation; and Inc., Manhasset, New York, under an educational grant from relaxation of the uterus and bronchial smooth muscle. Schering-Plough International. There was also an important beta-excitatory action, JULY • AUGUSTDownloaded 1991 from www.ccjm.org on September 27, 2021. For personal use only. All otherCLEVELAN uses requireD CLINI permission.C JOURNAL OF MEDICINE 337 ALPHA AND BETA BLOCKERS • PRICHARD TABLE I nism, inhibiting noradrena- EFFECTS OF RECEPTOR STIMULATION AND BLOCKADE line release, contain pre- synaptic receptors of the al- Organ/Iissue Receptor Stimulation causes Blockade causes pha-2 subtype.5 More re- Blood vessels Constriction Dilatation cently, investigations using (resistance vessels) Constriction Dilatation animals have identified fur- Dilatation Constrictio? n Heart Contractile forcet ther subtypes of alpha re- Heart rateî Bradycardia ß,>ß2 ceptors, as well as alpha-la, AV conduction? AV conduction! Contractile forceî Contractile force! alpha-lb, alpha-2a, and Spleen «i Contraction Relaxation alpha-2b receptors.6 M sphincter pupillae «2 Dilatation Contraction Thrombocytes <x2 Aggregation The distribution of re- Adenylcyclase Hyperglycemia Hypoglycemia ceptors is not the same in + Free fatty acidT Free fatty acid! ßi ß2 Intestine Relaxation all species or all organs. For Bronchi Relaxation Constriction Uterus Relaxation Constriction example, in some vascular §2>ß, Skeletal muscle Tremor Anti-tremor beds, such as the cerebral arteries of the dog, alpha-2 From van Zweiten.11 AV, atrioventricular; Î, increase; !, decrease receptors are more numer- ous than alpha-1 receptors.7 By comparison, the human TABLE 2 ALPHA AGONIST AND ANTAGONIST SELECTIVITY forearm has both alpha-1 and alpha-2 receptors.8 Receptor stimulated Receptors also vary in Agents or blocked Application their tissue and synaptic lo- Agonists cations. The receptors in Noradrenaline (neurotransmitter) + + Vasoconstrictor (a, + 0i2) «2 vascular smooth muscle Adrenaline (neurotransmitter) + a2 + | Vasoconstrictor (at + <X2) Phenylephrine >a, Vasoconstrictor (a,), decongestant (a2) that mediate the nerve im- Clonidine Antihypertensive (central a2) Guanfacine >a, pulses are postsynaptic re- Azepexole (B-HT 933) ceptors of the alpha-1 sub- B-HT 920 Antiglaucomatous (experimental) UK-14, 304 Experimental pharmacology type, whereas the receptors that mediate contraction in Antagonists Phentolamine a. + a, Pheochromocytoma preoperative response to hormonal stim- phase (a, + a2) ulation are extrasynaptic Tolazoline XX, Vasodilator (af + 0i2) 5 Prazosin Antihypertensive (peripheral Ctj) alpha-2 receptors. In vas- Doxazosin cular smooth muscle, the Terazosin alpha-1 receptors are lo- Trimazosin + Antihypertensive (peripheral Olj + ßj & ß2) Labetalol ß, ß2 cated in the adventitial lay- Corynanthine Experimental pharmacology er; the alpha-2 receptors are Rauwolscine diastereoisomers Yohimbine || found closer to the interior, Idazoxan where they respond to cir- 9 From van Zweiten." culating catecholamines. In the central nervous system, different functions cardiac stimulation (Table I). Isoprenaline was the have been identified for alpha-1 and alpha-2 receptors. most potent stimulant at the beta receptor; adrenaline The adrenergic postsynaptic receptors in the central was also effective. nervous system are predominantly alpha-2. Stimulation Subsequently, the alpha and beta receptors were fur- of these receptors produces a fall in blood pressure and ther delineated. The alpha receptors were subdivided bradycardia. Central alpha-1 receptors, demonstrated into alpha-1 and alpha-2 receptors. Both alpha-1 and by receptor-binding techniques,8 may mediate alpha- 2 receptors are found on the postsynaptic mem- baroreceptor reflex function. Alpha-1 blockade of these brane, where vasoconstriction is mediated. The nerve central receptors may be the reason that the alpha-1 endings that function as a negative feedback mecha- blocker prazosin does not produce reflex tachycardia.10 338 CLEVELAND CLINIDownloadedC JOURNAL from OF MEDICIN www.ccjm.orgE on September 27, 2021. For personal use only. All other uses require permission.VOLUME 58 NUMBER 4 ALPHA AND BETA BLOCKERS • PRICHARD Agents that are active at adrenergic receptors may TABLE 3 be classified by their alpha activity. Methoxamine and BETA AGONST AND ANTAGONIST SELECTIVITY phenylephrine are alpha-1 stimulants; clonidine and Receptors its analogues are alpha-2 stimulants; noradrenaline and stimulated or adrenaline stimulate both alpha-1 and alpha-2 recep- Agent blocked tors. Prazosin, doxazosin, terazosin, and urapidil are Agonists alpha-1-blocking agents; yohimbine and rauwolscine Noradrenaline (norepinephrine, neurotransmitter) Adrenaline (epinephrine, neurotransmitter) + + + g, <*2 are alpha-2-blocking drugs; phentolamine blocks both Dobutamine alpha-1 and alpha-2 receptors (Table 2).5,6'11 Isoprenaline (isoproterenol) Orciprenaline (metoproterenol) The beta receptors have also been divided into beta- Fenoterol 1 and beta-2 receptors. More recently, beta-3 receptors Pirbuterol Rimiterol have been described in animal studies.6 Ritodrine As with alpha receptors, beta receptors also differ in Salbutamol Terbutaline their distribution and function. Beta-1 receptors predominate in the human heart. However, beta-2 Antagonists Propranolol" receptors are also present, constituting 35% of the beta Alprenolol and other receptors in the right atrium. For example, beta recep- Pindolol > nonselective beta Oxprenolol + blockers ß, ß2 tors mediate increase in heart rate and force of con- Timolol traction and increase in conductivity. Among the Sotalol Practolol ß,>>ß; many responses mediated by beta-2 receptors are Atenolol relaxation of vascular and bronchial smooth muscle. Metoprolol Acebutolol Adrenergic agonists and antagonists can be distin- guished by their beta reactivity (Table 3). The agonist From van Zweiten." dobutamine is relatively beta-1-selective, although it also stimulates the beta-2 and alpha-1 receptors. strictor impulses needed in the erect posture to main- Xamoterol is a specific but partial agonist for the beta- tain blood pressure are blocked by the irreversible 1 receptor. Noradrenaline is much more effective on binding of the inhibitor to the receptor. the beta-1 receptor, whereas adrenaline stimulates On the other hand, if the block is competitive and both types of beta receptor. The antagonist the dosage is appropriate, the increased sympathetic propranolol is the most widely evaluated nonselective activity associated with standing is likely to result in (beta-1, beta-2) blocking drug and atenolol, the most sufficient reversal of the alpha-receptor inhibition so studied of the beta-1 inhibitory drugs. No beta-2- that a postural fall of blood pressure does not occur. At blocking drug is clinically available. high drug dosage, however, even the competitive block may be sufficient to prevent adequate compensatory
Recommended publications
  • TABLE 1 Studies of Antagonist Activity in Constitutively Active

    TABLE 1 Studies of Antagonist Activity in Constitutively Active

    TABLE 1 Studies of antagonist activity in constitutively active receptors systems shown to demonstrate inverse agonism for at least one ligand Targets are natural Gs and constitutively active mutants (CAM) of GPCRs. Of 380 antagonists, 85% of the ligands demonstrate inverse agonism. Receptor Neutral Antagonist Inverse Agonist Reference Human β2-adrenergic Dichloroisoproterenol, pindolol, labetolol, timolol, Chidiac et al., 1996; Azzi et alprenolol, propranolol, ICI 118,551, cyanopindolol al., 2001 Turkey erythrocyte β-adrenergic Propranolol, pindolol Gotze et al., 1994 Human β2-adrenergic (CAM) Propranolol Betaxolol, ICI 118,551, sotalol, timolol Samama et al., 1994; Stevens and Milligan, 1998 Human/guinea pig β1-adrenergic Atenolol, propranolol Mewes et al., 1993 Human β1-adrenergic Carvedilol CGP20712A, metoprolol, bisoprolol Engelhardt et al., 2001 Rat α2D-adrenergic Rauwolscine, yohimbine, WB 4101, idazoxan, Tian et al., 1994 phentolamine, Human α2A-adrenergic Napthazoline, Rauwolscine, idazoxan, altipamezole, levomedetomidine, Jansson et al., 1998; Pauwels MPV-2088 (–)RX811059, RX 831003 et al., 2002 Human α2C-adrenergic RX821002, yohimbine Cayla et al., 1999 Human α2D-adrenergic Prazosin McCune et al., 2000 Rat α2-adrenoceptor MK912 RX821002 Murrin et al., 2000 Porcine α2A adrenoceptor (CAM- Idazoxan Rauwolscine, yohimbine, RX821002, MK912, Wade et al., 2001 T373K) phentolamine Human α2A-adrenoceptor (CAM) Dexefaroxan, (+)RX811059, (–)RX811059, RS15385, yohimbine, Pauwels et al., 2000 atipamezole fluparoxan, WB 4101 Hamster α1B-adrenergic
  • Drug Class Review Beta Adrenergic Blockers

    Drug Class Review Beta Adrenergic Blockers

    Drug Class Review Beta Adrenergic Blockers Final Report Update 4 July 2009 Update 3: September 2007 Update 2: May 2005 Update 1: September 2004 Original Report: September 2003 The literature on this topic is scanned periodically. The purpose of this report is to make available information regarding the comparative effectiveness and safety profiles of different drugs within pharmaceutical classes. Reports are not usage guidelines, nor should they be read as an endorsement of, or recommendation for, any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Mark Helfand, MD, MPH Kim Peterson, MS Vivian Christensen, PhD Tracy Dana, MLS Sujata Thakurta, MPA:HA Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Oregon Health & Science University Copyright © 2009 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 4 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION .......................................................................................................................... 6 Purpose and Limitations of Evidence Reports........................................................................................ 8 Scope and Key Questions .................................................................................................................... 10 METHODS.................................................................................................................................
  • (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al

    (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak Et Al

    US008343962B2 (12) United States Patent (10) Patent N0.: US 8,343,962 B2 Kisak et al. (45) Date of Patent: *Jan. 1, 2013 (54) TOPICAL FORMULATION (58) Field of Classi?cation Search ............. .. 514/226.5, 514/334, 420, 557, 567 (75) Inventors: Edward T. Kisak, San Diego, CA (US); See application ?le fOr Complete Search history. John M. NeWsam, La Jolla, CA (US); _ Dominic King-Smith, San Diego, CA (56) References C‘ted (US); Pankaj Karande, Troy, NY (US); Samir Mitragotri, Goleta, CA (US) US' PATENT DOCUMENTS 5,602,183 A 2/1997 Martin et al. (73) Assignee: NuvoResearchOntano (CA) Inc., Mississagua, 6,328,979 2B1 12/2001 Yamashita et a1. 7,001,592 B1 2/2006 Traynor et a1. ( * ) Notice: Subject to any disclaimer, the term of this 7,795,309 B2 9/2010 Kisak eta1~ patent is extended or adjusted under 35 2002/0064524 A1 5/2002 Cevc U.S.C. 154(b) by 212 days. FOREIGN PATENT DOCUMENTS This patent is subject to a terminal dis- W0 WO 2005/009510 2/2005 claimer- OTHER PUBLICATIONS (21) APPI' NO‘, 12/848,792 International Search Report issued on Aug. 8, 2008 in application No. PCT/lB2007/0l983 (corresponding to US 7,795,309). _ Notice ofAlloWance issued on Apr. 29, 2010 by the Examiner in US. (22) Med Aug- 2’ 2010 Appl. No. 12/281,561 (US 7,795,309). _ _ _ Of?ce Action issued on Dec. 30, 2009 by the Examiner in US. Appl. (65) Prior Publication Data No, 12/281,561 (Us 7,795,309), Us 2011/0028460 A1 Feb‘ 3’ 2011 Primary Examiner * Raymond Henley, 111 Related U 5 Application Data (74) Attorney, Agent, or Firm * Foley & Lardner LLP (63) Continuation-in-part of application No.
  • Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse

    Metabolism and Pharmacokinetics in the Development of New Therapeutics for Cocaine and Opioid Abuse

    University of Mississippi eGrove Electronic Theses and Dissertations Graduate School 2012 Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse Pradeep Kumar Vuppala University of Mississippi Follow this and additional works at: https://egrove.olemiss.edu/etd Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Vuppala, Pradeep Kumar, "Metabolism And Pharmacokinetics In The Development Of New Therapeutics For Cocaine And Opioid Abuse" (2012). Electronic Theses and Dissertations. 731. https://egrove.olemiss.edu/etd/731 This Dissertation is brought to you for free and open access by the Graduate School at eGrove. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of eGrove. For more information, please contact [email protected]. METABOLISM AND PHARMACOKINETICS IN THE DEVELOPMENT OF NEW THERAPEUTICS FOR COCAINE AND OPIOID ABUSE A Dissertation presented in partial fulfillment of requirements for the degree of Doctor of Philosophy in Pharmaceutical Sciences in the Department of Pharmaceutics The University of Mississippi by PRADEEP KUMAR VUPPALA April 2012 Copyright © 2012 by Pradeep Kumar Vuppala All rights reserved ABSTRACT Cocaine and opioid abuse are a major public health concern and the cause of significant morbidity and mortality worldwide. The development of effective medication for cocaine and opioid abuse is necessary to reduce the impact of this issue upon the individual and society. The pharmacologic treatment for drug abuse has been based on one of the following strategies: agonist substitution, antagonist treatment, or symptomatic treatment. This dissertation is focused on the role of metabolism and pharmacokinetics in the development of new pharmacotherapies, CM304 (sigma-1 receptor antagonist), mitragynine and 7-hydroxymitragynine (µ-opioid receptor agonists), for the treatment of drug abuse.
  • The In¯Uence of Medication on Erectile Function

    The In¯Uence of Medication on Erectile Function

    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
  • Allergy Testing and History Form

    Allergy Testing and History Form

    Skin Testing Information and Consent 1. Skin Testing An allergy skin test is used to identify the substances that are causing your allergy symptoms. We will apply several extracts of common allergens to the skin and observe for a reaction. The reactions are then graded and confirmatory intradermal testing may be performed. This involves placing a small amount of extract under the skin of the upper arm. We then observe the reaction and record the results. On the day of testing please wear a short-sleeved shirt that can be pushed up comfortably to your shoulder. Allow 1-2 hours for your test session. You will need to stay on the premises during this time. Please do not bring children to your appointment. 2. Risks of Skin Testing Bleeding and infection may occur due to abrading of the skin. Any time the skin integrity is broken it puts on at risk for infection. However, this is a rare occurrence. The antigens used for testing are sterile and approved by the FDA. Occasionally, skin testing can trigger a severe allergic reaction requiring treatment with medications and/or treatment in the ER. Patients with asthma are at increased risk for triggering an asthma attack during testing. You should not undergo testing if you feel that you have allergy or asthma symptoms are currently under poor control. 3. Contraindications to Skin Testing Women who are pregnant or anyone who is currently taking Beta-Blockers, Tricyclic Anti-depressants or MAOI’s medications will NOT be skin tested. Please be sure to inform us of ALL your medications before the skin test is applied.
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    Health Reports for Mutual Recognition of Medical Prescriptions: State of Play

    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
  • Epidemiology of Depressive Disorders 21 Aetiology 22 Treatment of Depressive Disorders 40 Prognosis 51

    Epidemiology of Depressive Disorders 21 Aetiology 22 Treatment of Depressive Disorders 40 Prognosis 51

    The assessment of serotonin function in major depression MD Thesis William Richard Whale 2005 1 UMI Number: U201052 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. Dissertation Publishing UMI U201052 Published by ProQuest LLC 2014. Copyright in the Dissertation held by the Author. Microform Edition © ProQuest LLC. All rights reserved. This work is protected against unauthorized copying under Title 17, United States Code. ProQuest LLC 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106-1346 Abstract Major depression is a common psychiatric disorder with considerable associated morbidity and mortality. Investigations to understand the causes of depression and how it can be more effectively treated are high priority. The serotonergic system has been implicated in the aetiology and treatment of depression by a wealth of preclinical and clinical evidence. This includes findings that drugs increasing serotonin neurotransmission have antidepressant action and inhibition of serotonin synthesis (via tryptophan depletion) can induce relapse of symptoms in depressed patients. Neuroendocrine challenges are an established method of indirectly examining brain serotonergic function, utilising changes in the secretion of pituitary hormones influenced by tonic serotonergic activity at the level of the hypothalamus. This thesis describes the development of two such neuroendocrine challenge tests, using the selective serotonergic probes, zolmitriptan and citalopram. Orally administered zolmitriptan, licensed for the treatment of migraine, clearly elevated plasma growth hormone in healthy subjects.
  • Adrenoceptor Subtype 1Ian Marshall, Richard P

    Adrenoceptor Subtype 1Ian Marshall, Richard P

    Brifish Journal of Pharmacology (I995) 115, 781 - 786 1995 Stockton Press All rights reserved 0007-1188/95 $12.00 X Noradrenaline contractions of human prostate mediated by aClA- (cxlc) adrenoceptor subtype 1Ian Marshall, Richard P. Burt & *Christopher R. Chapple Department of Pharmacology, University College London, Gower Street, London WC1E 6BT and *Department of Urology, The Royal Hallamshire Hospital, Glossop Road, Sheffield SlO 2JF 1 The subtype of a1-adrenoceptor mediating contractions of human prostate to noradrenaline was characterized by use of a range of competitive and non-competitive antagonists. 2 Contractions of the prostate to either noradrenaline (pD2 5.5), phenylephrine (pD2 5.1) or methoxamine (pD2 4.4) were unaltered by the presence of neuronal and extraneuronal uptake blockers. Noradrenaline was about 3 and 10 times more potent than phenylephrine and methoxamine respectively. Phenylephrine and methoxamine were partial agonists. 3 Pretreatment with the alkylating agent, chlorethylclonidine (10-4 M) shifted the noradrenaline concentration-contraction curve about 3 fold to the right and depressed the maximum response by 31%. This shift is 100 fold less than that previously shown to be produced by chlorethylclonidine under the same conditions on OlB-adrenoceptor-mediated contractions. 4 Cumulative concentration-contraction curves for noradrenaline were competitively antagonized by WB 4101 (pA2 9.0), 5-methyl-urapidil (pA2 8.6), phentolamine (pA2 7.6), benoxathian (pA2 8.5), spiperone (pA2 7.3), indoramin (pA2 8.2) and BMY 7378 (pA2 6.6). These values correlated best with published pKi values for their displacement of [3H]-prazosin binding on membranes expressing cloned oczc-adrenoceptors and poorly with values from cloned lb- and cld-adrenoceptors.
  • United States Patent (19) (11) 4,310,524 Wiech Et Al

    United States Patent (19) (11) 4,310,524 Wiech Et Al

    United States Patent (19) (11) 4,310,524 Wiech et al. 45 Jan. 12, 1982 (54) TCA COMPOSITION AND METHOD FOR McMillen et al., Fed. Proc., 38,592 (1979). RAPD ONSET ANTDEPRESSANT Sellinger et al., Fed. Proc., 38,592 (1979). THERAPY Pandey et al., Fed. Proc., 38,592 (1979). 75) Inventors: Norbert L. Wiech; Richard C. Ursillo, Primary Examiner-Stanley J. Friedman both of Cincinnati, Ohio Attorney, Agent, or Firm-Millen & White 73) Assignee: Richardson-Merrell, Inc., Wilton, Conn. (57 ABSTRACT A method is provided for treating depression in a pa (21) Appl. No.: 139,498 tient therefrom and requiring rapid symptomatic relief, (22 Filed: Apr. 11, 1980 which comprises administering to said patient concur 51) Int. Cl. .................... A61K 31/33; A61K 31/135 rently (a) an effective antidepressant amount of a tricy clic antidepressant or a pharmaceutically effective acid (52) ...... 424/244; 424/330 addition salt thereof, and (b) an amount of an a-adrener 58) Field of Search ................................ 424/244, 330 gic receptor blocking agent effective to achieve rapid (56) References Cited onset of the antidepressant action of (a), whereby the PUBLICATIONS onset of said antidepressant action is achieved within Chemical Abst., vol. 66-72828m, (1967), Kellett. from 1 to 7 days. Chemical Abst, vol. 68-94371a, (1968), Martelli et al. A pharmaceutical composition is also provided which is Chemical Abst., vol. 74-86.048j, (1971), Dixit et al. especially adapted for use with the foregoing method. Holmberg et al., Psychopharm., 2,93 (1961). Svensson, Symp. Med. Hoechst., 13, 245 (1978). 17 Claims, No Drawings 4,310,524 1.
  • Stems for Nonproprietary Drug Names

    Stems for Nonproprietary Drug Names

    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
  • An in Silico Study of the Ligand Binding to Human Cytochrome P450 2D6

    An in Silico Study of the Ligand Binding to Human Cytochrome P450 2D6

    AN IN SILICO STUDY OF THE LIGAND BINDING TO HUMAN CYTOCHROME P450 2D6 Sui-Lin Mo (Doctor of Philosophy) Discipline of Chinese Medicine School of Health Sciences RMIT University, Victoria, Australia January 2011 i Declaration I hereby declare that this submission is my own work and to the best of my knowledge it contains no materials previously published or written by another person, or substantial proportions of material which have been accepted for the award of any other degree or diploma at RMIT university or any other educational institution, except where due acknowledgment is made in the thesis. Any contribution made to the research by others, with whom I have worked at RMIT university or elsewhere, is explicitly acknowledged in the thesis. I also declare that the intellectual content of this thesis is the product of my own work, except to the extent that assistance from others in the project‘s design and conception or in style, presentation and linguistic expression is acknowledged. PhD Candidate: Sui-Lin Mo Date: January 2011 ii Acknowledgements I would like to take this opportunity to express my gratitude to my supervisor, Professor Shu-Feng Zhou, for his excellent supervision. I thank him for his kindness, encouragement, patience, enthusiasm, ideas, and comments and for the opportunity that he has given me. I thank my co-supervisor, A/Prof. Chun-Guang Li, for his valuable support, suggestions, comments, which have contributed towards the success of this thesis. I express my great respect to Prof. Min Huang, Dean of School of Pharmaceutical Sciences at Sun Yat-sen University in P.R.China, for his valuable support.